HAAKON RAGDE, M.D.

Corporate Board Profile

Tech Score: 0/100

NORTHWEST BIOTHERAPEUTICS INC

Filing Date	Source Excerpt
2002-05-03	Haakon Ragde, M.D. Director Age 74 Dr. Ragde has served as a director since September 1998. On May 1, 2001, we entered into a consulting agreement with Dr. Ragde, a member of our board of directors, to engage him to advise us regarding development of our immunotherapy programs. This agreement provided that we would pay Dr. Ragde up to $48,000 per year and grant him the option to purchase, at fair market value, 5,000 shares of our Common Stock.
2003-03-24	Dr. Ragde has served as a director since September 1998. ... On May 1, 2001, we entered into a consulting agreement with Dr. Ragde, a member of our Board of Directors. Under this agreement he will advise us regarding development of our immunotherapy programs through April 30, 2002. This agreement provides that we will pay Dr. Ragde up to $48,000 per year and grant him the option to purchase, at fair market value, 5,000 shares of our Common Stock. As of April 30, 2002, Dr. Ragde is no longer engaged as a paid consultant to the Company but continues to serve on our Board of Directors. ... Current members of the Compensation Committee are Mr. Hutchinson, Dr. Ragde and Mr. Pines. ... Current members of the Audit Committee are Dr. Caudill, Mr. Hutchinson, Mr. Pines and Dr. Ragde.

Filing Date

Source Excerpt

2002-05-03

Haakon Ragde, M.D. Director Age 74 Dr. Ragde has served as a director since September 1998. On May 1, 2001, we entered into a consulting agreement with Dr. Ragde, a member of our board of directors, to engage him to advise us regarding development of our immunotherapy programs. This agreement provided that we would pay Dr. Ragde up to $48,000 per year and grant him the option to purchase, at fair market value, 5,000 shares of our Common Stock.

2003-03-24

Dr. Ragde has served as a director since September 1998. ... On May 1, 2001, we entered into a consulting agreement with Dr. Ragde, a member of our Board of Directors. Under this agreement he will advise us regarding development of our immunotherapy programs through April 30, 2002. This agreement provides that we will pay Dr. Ragde up to $48,000 per year and grant him the option to purchase, at fair market value, 5,000 shares of our Common Stock. As of April 30, 2002, Dr. Ragde is no longer engaged as a paid consultant to the Company but continues to serve on our Board of Directors. ... Current members of the Compensation Committee are Mr. Hutchinson, Dr. Ragde and Mr. Pines. ... Current members of the Audit Committee are Dr. Caudill, Mr. Hutchinson, Mr. Pines and Dr. Ragde.

Source material: SEC submissions metadata and DEF 14A proxy filings from EDGAR. Last updated: 2026-03-19